Bleomycin
- Generic Name
- Bleomycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C55H84N17O21S3
- CAS Number
- 11056-06-7
- Unique Ingredient Identifier
- 40S1VHN69B
- Background
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
- Indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
- Associated Conditions
- Hodgkin's Lymphoma, Malignant Pleural Effusion, Non-Hodgkin's Lymphomas, Squamous Cell Carcinoma (SCC), Teratocarcinoma, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma
- Associated Therapies
- Palliative Treatment
Bleomycin Jet Injections in Keloids
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT04582305
- Locations
- 🇳🇱
Eramsus Medical Centre, Dermatology department, Rotterdam, Zuid-Holland, Netherlands
Electrochemotherapy for Non-curable Gastric Cancer
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Zealand University Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT04139070
- Locations
- 🇩🇰
Department of Surgery, Zealand University Hospital, Køge, Denmark
Bleomycin Infusion (MMP®) to Repigment Achromic Scars
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Clinica Dermatologica Arbache ltda
- Target Recruit Count
- 50
- Registration Number
- NCT04046679
- Locations
- 🇧🇷
Clinica Dermatologica Arbache Ltda, São José Dos Campos, SÃO Paulo, Brazil
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT03755804
- Locations
- 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage I Lymphocyte-Depleted Classic HLAnn Arbor Stage II Hodgkin LymphomaLymphocyte-Rich Classic Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage II Mixed Cellularity Classic HLAnn Arbor Stage II Nodular Sclerosis Classic HLAnn Arbor Stage I Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 155
- Registration Number
- NCT03712202
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2018-03-26
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT03477448
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT03407144
- Locations
- 🇺🇸
University of Chicago ( Site 0066), Chicago, Illinois, United States
🇺🇸Cohen Children's Medical Center of New York ( Site 0052), New Hyde Park, New York, United States
🇺🇸Columbia University/Herbert Irving Cancer Center ( Site 0063), New York, New York, United States
Investigating Cardiovascular Adverse Events Related to Cancer Treatment
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 48
- Registration Number
- NCT03199300
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 500
- Registration Number
- NCT03159897
- Locations
- 🇮🇹
Ospedale Madonna delle Grazie - Ematologia, Matera, Italy
🇮🇹Presidio ospedaliero "A. TORTORA", Pagani, Italy
🇮🇹Istituto Clinico Humanitas - U.O. Ematologia, Rozzano (MI), Italy
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT03033914
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.